ADIM
KROS icon

Alpha DNA Investment Management’s Keros Therapeutics KROS Stock Holding History

Alpha DNA Investment Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-70
Closed -$4K – 383
2021
Q1 		$4K Buy
70
+27
+63% +$1.71K ﹤0.01% 412
2020
Q4 		$3K Buy
+43
New +$2.71K ﹤0.01% 418

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Alpha DNA Investment Management's KROS Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Keros Therapeutics (KROS) in Q2 2021, closing a stake of 70 shares — an estimated $4K sold.

Alpha DNA Investment Management first reported a position in KROS in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q1 2021. 80 funds tracked by Wall St. Rank hold KROS as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Keros Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 70 Keros Therapeutics shares in Q2 2021, an estimated $4K.
  • Alpha DNA Investment Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Keros Therapeutics position peaked at $4K in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.